# A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus

> **NCT06628362** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Carmot Therapeutics, Inc.** · enrollment: 360 (estimated)

## Conditions studied

- Overweight or Obese
- Type 2 Diabetes Mellitus (T2DM)

## Interventions

- **DRUG:** Placebo
- **DRUG:** Enicepatide

## Key facts

- **NCT ID:** NCT06628362
- **Lead sponsor:** Carmot Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-11-21
- **Primary completion:** 2026-06-01
- **Final completion:** 2026-09-24
- **Target enrollment:** 360 (ESTIMATED)
- **Last updated:** 2026-04-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06628362

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06628362, "A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT06628362. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*